Conferences

PUBLICATIONS

Faisal A, Innocenti P, Westwood I, Naud S, Schmitt J, Hayes A, Mak G, Gurden M, Bavetsias V, Cheung J, Woodward H, Sheldrake P, Atrash B, Burke R, Baker R, McAndrew C, Rowlands M, Valenti M, Workman P, Eccles S, Raynaud F, vanMontfort R, Hoelder S, Blagg J, Linardopoulos S. CCT271850, a novel, selective, highly potent and orally bioavailable Mps1 kinase inhibitor Presented at 2013 AACR Annual Meeting April 6-10 Washington DC

Faisal A, Naud S, Westwood I, Schmitt J, Hayes A, Gurden M, Bavetsias V, Berry T, Mak G, Innocenti P, Cheung J, Sheldrake P, Atrash B, Sun C, Matijssen B, Burke R, Baker R, McAndrew C, Rowlands M, Brough R, Lord CJ Ashworth A, Workman P, Eccles SA, Hoelder S, Raynaud FI, Montfort R, Blagg J and Linardopoulos S. Characterisation of CCT251455, a Potent, Selective and Orally Bioavailable MPS1/TTK Kinase Inhibitor. Presented at 2012 AACR Annual Meeting March 31 to April 4 Chicago IL

Moore AS, Faisal A, Bavetsias V, Gonzalez de Castro D, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Pearson ADJ, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S. Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736. Presented at the 53^rd American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, USA, Dec 10-13, 2011.

Moore AS, Faisal A, Bavetsias V, Gonzalez de Castro D, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Pearson ADJ, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S. The dual FLT3-Aurora inhibitor CCT241736 overcomes resistance to selective FLT3 inhibition driven by FLT3 ligand and FLT3 point mutations in acute myeloid leukemia. Presented at the 2011 AACR-NCI-EORTC Meeting, San Francisco, 12-16 November 2011

Moore AS, Faisal A, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Gonzalez de Castro D, Pearson ADJ, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S. Resistance to selective FLT3 inhibition, mediated by FLT3 ligand and FLT3-mutational change, can be overcome with the dual FLT3-Aurora inhibitor CCT137690. Presented at ESH-EHA Scientific Workshop on Acute Myeloid Leukemia Molecular. Mandelieu, France. 14-16 October, 2011

Bavetsias V, Moore AS, Faisal A, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Gonzalez de Castro D, Raynaud FI, Workman P, Pearson ADJ, Blagg J, Eccles SA, Linardopoulos S. CCT137690 is an orally bioavailable dual FLT3 / Aurora kinase inhibitor that potently reduces the growth of a FLT3-ITD positive AML human tumour xenograft model in vivo. Presented at the 16th SCI/RSC Medicinal Chemistry Symposium, Churchill College, Cambridge, UK. 11-14 September 2011

Moore AS, Faisal A, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Gonzalez de Castro D, Raynaud FI, Workman P, Pearson ADJ, Blagg J, Eccles SA, Linardopoulos S. CCT137690, a dual Inhibitor of Aurora and FLT3 Kinases, sensitizes FLT3-ITD positive acute myeloid leukemia and overcomes resistance to selective FLT3-inhibition. 102^nd AACR Annual Meeting Abstract 3554, Orlando, USA. 2-6 April 2011.

Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, Workman P, Blagg J, Raynaud FI, Eccles SA, Chesler L and Linardopoulos S. The Novel Aurora Kinase Inhibitor CCT137690 is Active Against MYCN-Amplified Neuroblastoma in vitro and in vivo. Presented at Cell cycle Regulators/Inhibitors and Cancer: February 5-8 2011 Vienna, Austria

Moore AS, Faisal A, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Raynaud FI, Workman P, Pearson ADJ, Blagg J, Eccles SA, Linardopoulos S. Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo. ASH Annual Meeting and Exposition Abstract 3289, Orlando, USA. 4-7 December 2010.

Faisal A, Saurin A, Gregory B, Foxwell B and Parker PJ. MyD88 acts as a scaffold to couple Protein Kinase C epsilon to Toll like Receptors. Presented at Innate Immunity: Signaling Mechanisms: February 24 – 29 2008 Keystone Resort · Keystone, Colorado.

Faisal A, Kleiner S, Nagamine Y. Non-Redundant role of Shc A in Erk regulation by cytoskeleton reorganization. Presented at Genes and Cancer: December 8-10 2003 University of Warwick UK. Was awarded Bursary to attend the meeting.

Faisal A, el-Shemerly M, Hess D, Nagamine Y. Serine/threonine phosphorylation of ShcA. Regulation of protein-tyrosine phosphatase-pest binding and involvement in insulin signaling. 3rd International Conference on Signal Transduction: May 17-23 2002 Dubrovnik, Croatia